Propanc Biopharma Pushes Ahead with Cancer Stem Cell Therapy

TL;DR

**PPCB is a high-risk, pre-revenue biotech with an ambitious clinical timeline for its cancer stem cell therapy, making it a speculative bet on future financing and trial success.**

AI Summary

Propanc Biopharma, Inc. (PPCB) reported no revenue for the fiscal year ended June 30, 2025, continuing its development-stage status. The company is focused on its lead product candidate, PRP, a novel proenzyme therapy for solid tumors, which received Orphan Drug Designation for pancreatic cancer from the U.S. FDA in June 2017. PPCB plans to commence its Investigational Medicinal Product Dossier and study proposal in 2025, with a First-In-Human Phase Ib study in advanced solid tumor patients targeted for the second half of calendar year 2026, contingent on sufficient financing. The company also has a POP1 joint research program with the Universities of Jan and Granada to develop a backup clinical compound, with a second two-year agreement successfully concluding in late 2024 and a third planned for three years. PPCB's strategy centers on differentiation therapy to induce cancer cell senescence rather than cell death, aiming to prevent recurrence and metastasis.

Why It Matters

Propanc Biopharma's focus on differentiation therapy and targeting cancer stem cells represents a potentially transformative approach in oncology, moving beyond traditional chemotherapy's limitations. If successful, PRP could offer a new treatment paradigm for patients with advanced solid tumors, particularly pancreatic, ovarian, and colorectal cancers, where current options are often inadequate. For investors, this filing highlights the significant clinical development milestones planned for 2025 and 2026, which, while capital-intensive, could unlock substantial value if PRP demonstrates efficacy. The competitive landscape in oncology is fierce, but a novel, non-toxic therapy could carve out a significant market niche and impact patient outcomes globally.

Risk Assessment

Risk Level: high — The company is a pre-revenue biopharmaceutical entity with no products on the market, relying entirely on future financing to fund its ambitious clinical trial plans for PRP. The filing explicitly states, "our ability to continue as a going concern absent new debt or equity financings" and "our ability to obtain adequate new financing" as critical risks. Furthermore, the aggregate market value of non-affiliate common equity was only $347,895 as of December 31, 2024, indicating a very small market capitalization and high volatility potential.

Analyst Insight

Investors should approach PPCB with extreme caution, recognizing it as a highly speculative investment. Monitor closely for updates on financing rounds and the initiation and progress of the planned Phase Ib clinical trial in late 2026, as these will be critical determinants of the company's viability and future prospects.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0.00

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0.0004 — closing price per share (on December 31, 2024, reflecting low market valuation)
• $347,895 — aggregate market value of non-affiliate common equity (as of December 31, 2024, indicating a micro-cap company)
• 43.5% — cash back benefit (from overseas R&D expenses via Board of Innovation and Science Australia)
• 9.0 months — mean survival (for patients in suppository study, compared to 5.6 months life expectation)
• 41.3% — patients with longer survival (19 out of 46 patients in the suppository study)
• 85.9% — tumor inhibition (in pancreatic tumor model with PRP treatment)
• 50% — tumor inhibition (in ovary tumor model with PRP treatment)
• 1:6 — synergistic ratio (of trypsinogen to chymotrypsinogen in PRP)
• 12,806,747 — shares of Common Stock issued and outstanding (as of September 24, 2025)

Key Players & Entities

• Propanc Biopharma, Inc. (company) — registrant
• PRP (company) — lead product candidate
• U.S. Food and Drug Administration (regulator) — granted Orphan Drug Designation
• June 2017 (date) — Orphan Drug Designation received
• 2025 (date) — planned start of Investigational Medicinal Product Dossier
• 2026 (date) — planned start of Phase Ib clinical trial
• Peter MacCallum Cancer Centre (company) — planned clinical trial site
• Julian Kenyon (person) — Chief Scientific Officer
• $347,895 (dollar_amount) — aggregate market value of non-affiliate common equity as of December 31, 2024
• 869,738,031 (dollar_amount) — shares of common stock outstanding on December 31, 2024

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company's ability to continue its operations and advance its product candidates, including the planned Phase Ib study for PRP, is heavily dependent on its ability to secure substantial future financing. Without sufficient capital, PPCB may be unable to fund its research and development activities, potentially leading to a halt in progress or even bankruptcy.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: Propanc's lead product candidate, PRP, must undergo rigorous clinical trials and obtain regulatory approval from bodies like the FDA. There is no guarantee that PRP will demonstrate sufficient safety and efficacy in human trials to gain approval, which is a lengthy and expensive process with a high failure rate for drug candidates.
• Development Stage and Lack of Revenue [high — operational]: As a development-stage biopharmaceutical company, PPCB has not generated any revenue to date. Its success hinges entirely on the successful development and commercialization of its product candidates. This lack of established revenue streams and reliance on future breakthroughs presents a significant operational risk.
• Competition in Oncology Market [medium — market]: The oncology market is highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing novel therapies. PPCB faces competition from existing treatments and other investigational drugs targeting similar cancers, which could impact market penetration and pricing if PRP is eventually approved.
• Low Market Valuation [medium — financial]: The company's closing price per share was $0.0004 as of December 31, 2024, and its aggregate market value of non-affiliate common equity was $347,895. This reflects a micro-cap status and indicates significant investor skepticism or lack of confidence in the company's prospects.
• Reliance on Key Personnel and Research Partners [medium — operational]: The company's progress is dependent on its management team and its collaborations, such as the POP1 joint research program with the Universities of Jan and Granada. The loss of key personnel or the termination of these research agreements could significantly impede development efforts.
• Orphan Drug Designation Limitations [low — regulatory]: While PRP has Orphan Drug Designation for pancreatic cancer, this designation provides certain incentives but does not guarantee market exclusivity or regulatory approval. The designation is specific to certain indications and may not extend to all potential uses of the therapy.

Industry Context

The biopharmaceutical industry, particularly the oncology sector, is characterized by intense competition, high R&D costs, and stringent regulatory hurdles. Companies like Propanc Biopharma are developing novel therapies targeting unmet needs, but face significant challenges from established players and emerging technologies. Trends include a focus on targeted therapies, immunotherapy, and innovative drug delivery mechanisms.

Regulatory Implications

Propanc's development of PRP is subject to strict FDA regulations, requiring extensive preclinical and clinical testing to demonstrate safety and efficacy. The Orphan Drug Designation provides some advantages but does not guarantee approval. Any delays or failures in the regulatory process pose significant risks to the company's future.

What Investors Should Do

1. Monitor financing activities closely.
2. Evaluate clinical trial progress and data.
3. Assess competitive landscape and market potential.
4. Consider the high-risk, speculative nature of the investment.

Key Dates

• 2017-06-01: Orphan Drug Designation — Received Orphan Drug Designation from the U.S. FDA for PRP for pancreatic cancer, providing potential market exclusivity and other incentives.
• 2024-12-31: Low Share Price — Closing price per share was $0.0004, indicating a very low market valuation and potential financial distress.
• 2024-12-31: Low Market Capitalization — Aggregate market value of non-affiliate common equity was $347,895, confirming micro-cap status and limited investor interest.
• 2024-12-01: POP1 Research Agreement Conclusion — Second two-year agreement for the POP1 joint research program with Universities of Jan and Granada successfully concluded, with a third planned.
• 2025-01-01: Planned Investigational Medicinal Product Dossier — Company plans to commence its Investigational Medicinal Product Dossier and study proposal, a critical step towards clinical trials.
• 2026-07-01: Targeted First-In-Human Study — Targeting the second half of calendar year 2026 for a Phase Ib study in advanced solid tumor patients, contingent on financing.

Glossary

Proenzyme Therapy

A therapeutic approach that uses inactive precursor enzymes (proenzymes) which are activated at the target site, potentially offering more controlled and localized therapeutic effects. (Propanc's lead product candidate, PRP, is a proenzyme therapy aimed at treating solid tumors.)

Orphan Drug Designation

A status granted by regulatory agencies (like the FDA) to drugs intended to treat rare diseases or conditions, offering incentives such as market exclusivity and tax credits. (PRP has received this designation for pancreatic cancer, which could be a significant advantage if the drug is approved.)

Senescence

A process where cells stop dividing and growing, often triggered by damage or stress. In cancer therapy, inducing senescence can prevent tumor growth and recurrence. (Propanc's strategy focuses on inducing cancer cell senescence rather than cell death, aiming to prevent metastasis and recurrence.)

Investigational Medicinal Product Dossier

A comprehensive document containing all the necessary information about an investigational drug, required for submission to regulatory authorities to gain approval for clinical trials. (The company plans to commence this dossier in 2025, a prerequisite for initiating human studies.)

Synergistic Ratio

The ratio of two or more substances that, when combined, produce an effect greater than the sum of their individual effects. (The 1:6 synergistic ratio of trypsinogen to chymotrypsinogen in PRP is a key characteristic of its formulation.)

Micro-cap Company

A company with a very small market capitalization, typically between $50 million and $300 million, though definitions can vary. Propanc's market cap is significantly below this range. (Propanc's market valuation indicates it is a micro-cap company, often associated with higher risk and volatility.)

Year-Over-Year Comparison

As Propanc Biopharma, Inc. is a development-stage company with no revenue, year-over-year financial comparisons are not applicable. The company continues to operate without generating sales, with its focus remaining on advancing its lead product candidate, PRP, through the development pipeline. Key developments since the last filing would likely pertain to progress in research, potential financing rounds, and updates on regulatory interactions, rather than changes in revenue or profitability metrics.

Key Financial Figures

• $0.001 — ) of the Act: Common Stock, par value $0.001 per share Indicate by check mark if t
• $3 — ommon equity held by non-affiliates was $3 47,895 computed by reference to the clo
• $0.0004 — s, Inc. on December 31, 2024 (which was $0.0004 per share), based on 869,738,031 shares
• $111 billion — tic cancer market is projected to reach $111 billion by 2027. To date, recombinant trypsin

Filing Documents

• form10-k.htm (10-K) — 3106KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• audit_001.jpg (GRAPHIC) — 30KB
• 0001493152-25-016069.txt ( ) — 14068KB
• ppcb-20250630.xsd (EX-101.SCH) — 72KB
• ppcb-20250630_cal.xml (EX-101.CAL) — 84KB
• ppcb-20250630_def.xml (EX-101.DEF) — 391KB
• ppcb-20250630_lab.xml (EX-101.LAB) — 669KB
• ppcb-20250630_pre.xml (EX-101.PRE) — 552KB
• form10-k_htm.xml (XML) — 2009KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 27 Item 1B. Unresolved Staff Comments 27 Item 1C. Cybersecurity 27 Item 2.

Properties

Properties 27 Item 3.

Legal Proceedings

Legal Proceedings 27 Item 4. Mine Safety Disclosure 27 Part II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 28 Item 6. [Reserved] 29 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 35 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 36 Item 9A.

Controls and Procedures

Controls and Procedures 36 Item 9B. Other Information 38 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 38 Part III Item 10. Directors, Executive Officers and Corporate Governance 38 Item 11.

Executive Compensation

Executive Compensation 45 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 50 Item 13. Certain Relationships and Related Transactions, and Director Independence 51 Item 14. Principal Accounting Fees and Services 52 Part IV Item 15. Exhibits and Financial Statement Schedules 53

Signatures

Signatures 59 2 Forward-Looking This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including: any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words "may," "might," "will," "will likely result," "would," "should," "estimate," "intend," "continue," "believe," "expect," "plan," "project," "forecast," "anticipate," "seek," "continue," "target" or the negative of such terms or other similar expressions. The ultimate correctness of these forward-looking statements is dependent upon a number of known and unknown risks and events and is subject to various uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance or achievements expressed or implied by these The following important factors, among others, could affect our future results and events, causing those results and events to differ materially from those views expressed or implied in our forward-looking statements: our ability to continue as a going concern absent new debt or equity financings; our ability to successfully remediate material weaknesses in our internal controls; our ability to reach research and development milestones as planned and within proposed budgets; our ability to control costs;

View Full Filing

View this 10-K filing on SEC EDGAR